- Stocks
- Healthcare
- NASDAQ: CBIO

Price (delayed)

$4.33

Market cap

$135.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.36

Enterprise value

$54.18M

The company's equity rose by 37% QoQ and by 7% YoY

Catalyst Biosciences's debt has decreased by 12% YoY and by 10% QoQ

CBIO's quick ratio has surged by 64% since the previous quarter but it is down by 15% year-on-year

CBIO's EPS is down by 15% since the previous quarter but it is up by 7% year-on-year

CBIO's gross margin has dropped by 103% since the previous quarter and by 103% year-on-year

CBIO's gross profit has dropped by 101% since the previous quarter and by 101% year-on-year

What are the main financial stats of CBIO

Market
Valuations
Earnings

Shares outstanding

31.35M

Market cap

$135.74M

Enterprise value

$54.18M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.3

Price to sales (P/S)

20.32

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.96

Revenue

$6.05M

EBIT

-$74.63M

EBITDA

-$74.47M

Free cash flow

-$74.86M

Per share
Balance sheet
Liquidity

EPS

-$3.36

Free cash flow per share

-$2.64

Book value per share

$3.32

Revenue per share

$0.21

TBVPS

$4.19

Total assets

$119.08M

Total liabilities

$14.99M

Debt

$1.48M

Equity

$104.09M

Working capital

$102.34M

Debt to equity

0.01

Current ratio

8.22

Quick ratio

7.62

Net debt/EBITDA

1.1

Margins
Efficiency
Dividend

EBITDA margin

-1,231.1%

Gross margin

-1.9%

Net margin

-1,233.7%

Operating margin

-1,235.6%

Return on assets

-66.4%

Return on equity

-77.9%

Return on invested capital

-152.7%

Return on capital employed

-71.1%

Return on sales

-1,233.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Catalyst Biosciences stock price performed over time

Intraday

1.17%

1 week

-4.84%

1 month

3.59%

1 year

-44.98%

YTD

-31.38%

QTD

-14.09%

How have Catalyst Biosciences's revenue and profit performed over time

Revenue

$6.05M

Gross profit

-$115,000

Operating income

-$74.74M

Net income

-$74.63M

Gross margin

-1.9%

Net margin

-1,233.7%

CBIO's gross margin has dropped by 103% since the previous quarter and by 103% year-on-year

CBIO's gross profit has dropped by 101% since the previous quarter and by 101% year-on-year

CBIO's revenue has dropped by 71% since the previous quarter and by 63% year-on-year

The net income has plunged by 69% YoY and by 33% from the previous quarter

What is Catalyst Biosciences's growth rate over time

What is Catalyst Biosciences stock price valuation

P/E

N/A

P/B

1.3

P/S

20.32

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

8.96

CBIO's EPS is down by 15% since the previous quarter but it is up by 7% year-on-year

The company's equity rose by 37% QoQ and by 7% YoY

CBIO's P/B is 30% above its 5-year quarterly average of 1.0

The stock's price to sales (P/S) is 101% more than its last 4 quarters average of 10.1

CBIO's revenue has dropped by 71% since the previous quarter and by 63% year-on-year

How efficient is Catalyst Biosciences business performance

CBIO's ROIC has plunged by 96% YoY and by 37% from the previous quarter

Catalyst Biosciences's ROA has plunged by 51% YoY and by 30% from the previous quarter

The ROE has dropped by 50% year-on-year and by 30% since the previous quarter

What is CBIO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CBIO.

How did Catalyst Biosciences financials performed over time

CBIO's quick ratio has surged by 64% since the previous quarter but it is down by 15% year-on-year

CBIO's current ratio has surged by 63% since the previous quarter but it is down by 10% year-on-year

Catalyst Biosciences's debt is 99% lower than its equity

Catalyst Biosciences's debt to equity has shrunk by 50% QoQ and by 50% YoY

The company's equity rose by 37% QoQ and by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.